Rubicin Dosage/Direction for Use

For intravenous (IV) infusion only: Do not administer intramuscularly (IM) or subcutaneously (SC) because of the potential for development of local tissue necrosis if administered through these routes.
The total cumulative dose of doxorubicin hydrochloride should not exceed 550 mg/m² because of the risk of potentially irreversible cardiotoxicity, but higher cumulative doses may be tolerated when dexrazoxane is used concomitantly as a cardioprotectant. If previous or concomitant therapy includes the use of other potentially cardiotoxic agents (e.g., cyclophosphamide, irradiation of the cardiac region), total doxorubicin hydrochloride should not exceed 400 mg/m². The total dosage of doxorubicin hydrochloride should include any previous or concomitant therapy with other anthracyclines or related compounds.
As A Single Agent: Commonly Used Adult Dosage Schedule: 60 to 75 mg/m² body surface area as a single IV injection every 21 days.
Alternative Adult Dosage Schedule: 20 mg/m² body surface area as a single IV injection in weekly doses has been reported to reduce the incidence of congestive heart failure.
30 mg/m² body surface area as a single IV injection on each of 3 successive days repeated every 4 weeks has also been used; this schedule is usually associated with a higher incidence of stomatitis.
In Combination Chemotherapy: In combination with other chemotherapy drugs, the most commonly used dosage of Doxorubicin is 40 to 60 mg/m² body surface area as a single IV injection every 21 to 28 days.
Dosage Adjustments: In a clinical study, patients who experienced neutropenic fever/infection while receiving the combination of doxorubicin/cyclophosphamide could have dose modifications of the regimen up to 75% of the starting doses. When necessary, the next cycle of treatment was delayed until the absolute neutrophil count (ANC) was ≥1000 cells/mm³ and the platelet count was ≥100,000 cells/mm³ and nonhematologic toxicities had resolved.
Dose reduction of Doxorubicin is recommended in patients with hepatic impairment with the following plasma bilirubin concentrations: See table.

Click on icon to see table/diagram/image

Doxorubicin should not be administered to patients with severe hepatic impairment. (see Contraindications).